Partner Gardner Davis was quoted in an article in Agenda, “Does Federal Deal Scrutiny Signal New M&A Risk?” about potential changes in the M&A landscape under the Trump administration.
The vast majority of corporate transactions won’t end up in the government’s cross hairs, Davis said. But for the small number of deals facing “unexpected regulatory turbulence,” such as the proposed merger between AT&T and Time Warner, the heightened scrutiny appears to be the result of “political animosity as opposed to traditional regulatory activity,” he said.
Companies, in turn, may be met with unwelcome unpredictability, Davis added. “Nobody in business likes this uncertainty. Moreover, the uncertainty ripples through the economy because rational economic decisions consistent with established law no longer control,” he said. “At a basic level, the rule of law does not anticipate politicians’ picking winners and losers like this.”
(Subscription required.)
The vast majority of corporate transactions won’t end up in the government’s cross hairs, Davis said. But for the small number of deals facing “unexpected regulatory turbulence,” such as the proposed merger between AT&T and Time Warner, the heightened scrutiny appears to be the result of “political animosity as opposed to traditional regulatory activity,” he said.
Companies, in turn, may be met with unwelcome unpredictability, Davis added. “Nobody in business likes this uncertainty. Moreover, the uncertainty ripples through the economy because rational economic decisions consistent with established law no longer control,” he said. “At a basic level, the rule of law does not anticipate politicians’ picking winners and losers like this.”
(Subscription required.)
People
Related News
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."
July 18, 2025
In the News
Aaron Maguregui Highlights Potential Compliance Concerns in Pre-Tax Wellness Claims
Foley & Lardner LLP partner Aaron Maguregui commented in The New York Times article, "Hot Dogs for Insomnia? A Kennedy Aide's Start-Up Can Get You a Tax Break," sharing insight on the growing use of medical necessity letters to support tax-advantaged purchases of wellness products.